留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

替吉奥治疗晚期乳腺癌的研究进展

郑婷 钱其军

郑婷, 钱其军. 替吉奥治疗晚期乳腺癌的研究进展[J]. 药学实践与服务, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
引用本文: 郑婷, 钱其军. 替吉奥治疗晚期乳腺癌的研究进展[J]. 药学实践与服务, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
Citation: ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021
基金项目: 国家科技重大专项(No.2013ZX10002-010-007)

Progress on S-1 in the treatment of advanced breast cancer

  • 摘要: 替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。
  • [1] Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
    [2] 邬晓敏,章烨,朱为民,等.培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察[J].中国癌症杂志,2011,21(2):159-160.
    [3] 汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585.
    [4] Muro K,Boku N,Shimada Y,et al.Irinotecan plus S-1(IRIS)versus fluorouracil and folinic acid plus irinotecan(FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a randomised phase 2/3 non-inferiority study(FIRIS study)[J].Lancet Oncol,2010,11(9):853-860.
    [5] Ueno H,Okusaka T,Furuse J,et al.Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy(GSTherapy) in patients with metastatic pancreatic cancer[J].Jpn J Clin Oncol,2011,41(8):953-958.
    [6] Saito Y,Oshitanai R,Terao M,et al.Post-marketing safety evaluation of S-1 in patients withinoperable or recurrent breast cancer: especially in patients treated with S-1 1 trastuzumab[J].Jpn J Clin Oncol, 2011,41(9):1051-1058.
    [7] Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG) [J].GanTo Kagaku Ryoho,2014,41(10):1221-1225.
    [8] 马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502.
    [9] Malet-Martino M,Martino R. Clinical studies of three oralprodrugs of 5-fluorouracil(capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
    [10] Ito Y,Osaki Y,Tokudome N,et al.Efficacy of S-1 in heavilypretreated patients with metastatic breast cancer:cross-resistance to capecitabine[J].Breast Cancer,2009,16(2):126.
    [11] Saeki T,Takashima S,Sano M,et al.Aphase Ⅱ study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group[J].Breast Cancer,2004,11(2):194-202.
    [12] Shien T,Shimizu C,Akashi-Tanakal S,et al.Clinical efficacy of S-1 in pretreated metastatic breast cancer patients[J].Jpn J Clin Oncol,2008,38(3):172-175.
    [13] Vici P,Giotta F,Di Lauro L,et al.A multicenter phase Ⅱ randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer:a gruppo oncologico Italia meridionale study[J].Oncology,201l,81(3-4):230-236.
    [14] Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phaseⅡ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
    [15] Yamamoto D,Iwase S,Yoshida H,et al.Efficacy of S-1 in patients with capecitabine-resistantbreast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial[J].Anticancer Res,2010,30(9): 3827-3831.
    [16] Mukai H, Takashima T, HozumiY,et al.Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC) [J].Jpn J Clin Oncol, 2010,40(8):811-814.
    [17] Nohara T,Iwamoto M,Sumiyoshi K, et al.Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer[J]. Oncol Let,2010,1(4): 669-672.
    [18] Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].GanTo Kagaku Ryoho. 2014,41(10):1221-1225.
    [19] Kobayashi Y, Kadoya T, Kanno E,et al.A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast[J].GanTo Kagaku Ryoho,2012,39(9):1403-1406.
    [20] Tazawa K, Tsuchiya Y, Shinbo M,et al.Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer[J].GanTo Kagaku Ryoho, 2011,38(3):423-425.
    [21] Yoshida H, Yamamoto D, Kanematsu S,et al.A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(13):2901-2903.
    [22] Takeyama H, Kyoda S, Yamashita A,et al.A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy[J].GanTo Kagaku Ryoho,2011,38(11):1873-1875.
    [23] Mori T, Yoshimura G, Ito D,et al.Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term[J].GanTo Kagaku Ryoho,2011,38(9):1495-1498.
    [24] Kubo H, Kijima D, Tada K,et al.A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(7):1325-1327.
    [25] Kato M, Kitayama J, Yamaguchi H,et al.Three cases of metastatic breast cancer effectively treated with S-1 therapy[J].GanTo Kagaku Ryoho,2010,37(5):903-906.
    [26] Aoyagi H, Kaneko J, Makinose T,et al.A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies[J].GanTo Kagaku Ryoho,2009,36(12):2474-2476.
    [27] Takashima T, Nakayama T, Yoshidome K,et al.Phase Ⅱ study of s-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res, 201434: 3583-3588 .
    [28] Ishida K.A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1plus trastuzumab[J].GanTo Kagaku Ryoho,2013,40(10):1385-1387.
    [29] Nakayama T, Morita S, Takashima T,et al.Phase Ⅰ study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res,2011,31(9):3035-3039.
    [30] Tokugawa T, Kobayashi A, Okubo K,et al.A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab[J].GanTo Kagaku Ryoho,2009,36(4):679-682.
  • [1] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [2] 张敏, 汪晓河, 周阳云, 石美智, 韩忻云, 韩向晖, 陈君君.  基于网络药理学和分子对接的苦参抗乳腺癌潜在机制研究 . 药学实践与服务, 2023, 41(12): 722-732. doi: 10.12206/j.issn.2097-2024.202302001
    [3] 马小雨, 罗彩萍, 刘悦.  代谢组学在乳腺癌诊疗中应用的研究进展 . 药学实践与服务, 2023, 41(3): 139-145. doi: 10.12206/j.issn.2097-2024.202109112
    [4] 叶琳岚, 贺春晖, 朱旭婷, 李霞.  苯乙双胍联合己糖激酶抑制剂诱导三阴性乳腺癌细胞凋亡 . 药学实践与服务, 2022, 40(3): 248-253. doi: 10.12206/j.issn.1006-0111.202103045
    [5] 周菊香, 王双英, 佘建涛, 曾贤良, 张继红.  肾衰竭对乳腺癌患者多西他赛暴露和不良反应的影响 . 药学实践与服务, 2022, 40(6): 571-575. doi: 10.12206/j.issn.2097-2024.202203068
    [6] 卢进, 赵新才, 陈蓓蓉, 赵赟, 王婧, 霍炎.  药师对1例转移性乳腺癌术后伴癌痛患者的药学监护 . 药学实践与服务, 2021, 39(4): 359-361. doi: 10.12206/j.issn.1006-0111.202101028
    [7] 周瑾, 李盛建, 覃福礼, 杨新颖, 张晓琳, 赵亮.  月腺大戟素A通过干扰PKD1介导的MEK/ERK和PI3K/AKT信号通路抑制乳腺癌细胞增殖的研究 . 药学实践与服务, 2020, 38(3): 241-244, 276. doi: 10.12206/j.issn.1006-0111.201912008
    [8] 曹青青, 李盛建, 李云青, 葛继云, 陈俊, 周瑾, 钱跹, 赵亮.  月腺大戟的化学成分及其乳腺癌细胞毒活性研究 . 药学实践与服务, 2019, 37(4): 309-313,317. doi: 10.3969/j.issn.1006-0111.2019.04.005
    [9] 林莉莉, 黄爱文, 林美钦, 方婕, 沈钦勇, 宋洪涛.  替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价 . 药学实践与服务, 2019, 37(6): 563-570. doi: 10.3969/j.issn.1006-0111.2019.06.018
    [10] 唐杰, 林厚文, 孙凡.  海绵来源的smenospongine诱导乳腺癌MCF7细胞凋亡机制研究 . 药学实践与服务, 2018, 36(5): 399-402,421. doi: 10.3969/j.issn.1006-0111.2018.05.004
    [11] 朱文玉, 姜齐, 张亮, 吴涓, 王洁, 丁红梓.  晚期非小细胞肺癌两种一线化疗方案的疗效观察和药物经济学分析 . 药学实践与服务, 2018, 36(2): 176-179. doi: 10.3969/j.issn.1006-0111.2018.01.017
    [12] 王筱婧, 王东兴, 范洁, 高越, 张海.  泽漆抑制三阴乳腺癌MDA-MB-231细胞及其凋亡机制研究 . 药学实践与服务, 2017, 35(4): 337-340,358. doi: 10.3969/j.issn.1006-0111.2017.04.012
    [13] 齐婧.  阿瑞匹坦对乳腺癌AC方案化疗后中重度呕吐患者的二级预防 . 药学实践与服务, 2017, 35(2): 158-160,181. doi: 10.3969/j.issn.1006-0111.2017.02.015
    [14] 杨喜晶, 周福平, 张迁, 钱其军.  化疗药物治疗双原发肿瘤继发急性白血病1例及文献复习 . 药学实践与服务, 2015, 33(5): 453-456. doi: 10.3969/j.issn.1006-0111.2015.05.020
    [15] 蒋琦, 钱其军.  化疗药物靶向肿瘤相关免疫抑制性细胞的研究进展 . 药学实践与服务, 2015, 33(2): 163-166,182. doi: 10.3969/j.issn.1006-0111.2015.02.019
    [16] 黄景彬, 钟延强.  乳腺癌靶向治疗的新策略 . 药学实践与服务, 2011, 29(5): 324-327.
    [17] 王晶, 赵娜萍, 舒丽芯, 刘斌, 张婉露, 严天虹, 潘勇华, 张黎.  参麦注射液联合TE化疗方案治疗进展期乳腺癌的临床观察研究 . 药学实践与服务, 2011, 29(3): 184-187,203.
    [18] 官东秀, 冯祚臻.  临床药师对1例服用分子靶向药物吉非替尼的肿瘤患者的药学监护 . 药学实践与服务, 2010, 28(4): 310-312.
    [19] 王洋, 郑唯强.  雌激素及三苯氧胺对MCF-7乳腺癌细胞BP1基因表达的影响 . 药学实践与服务, 2005, (4): @-@.
    [20] 赵强, 常英, 潘靖, 张军东.  云硒冲剂对乳腺癌术后化疗患者免疫功能的影响 . 药学实践与服务, 2004, (3): 156-157.
  • 加载中
计量
  • 文章访问数:  3141
  • HTML全文浏览量:  238
  • PDF下载量:  182
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-02-09
  • 修回日期:  2015-06-04

替吉奥治疗晚期乳腺癌的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.021
    基金项目:  国家科技重大专项(No.2013ZX10002-010-007)

摘要: 替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。

English Abstract

郑婷, 钱其军. 替吉奥治疗晚期乳腺癌的研究进展[J]. 药学实践与服务, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
引用本文: 郑婷, 钱其军. 替吉奥治疗晚期乳腺癌的研究进展[J]. 药学实践与服务, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
Citation: ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021
参考文献 (30)

目录

    /

    返回文章
    返回